Seminars in Nuclear Medicine
Volume 34, Issue 3 , Pages 166-179 , July 2004

Positron emission tomography in the evaluation of lymphoma

  • Ora Israel

      Affiliations

    • Department of Nuclear Medicine, Rambam Medical Center and B. Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa, Israel
    • Corresponding Author Information Address reprint requests to Ora Israel, MD, Department of Nuclear Medicine, Rambam Medical Center, Haifa 35254, Israel
    • ,
  • Zohar Keidar

      Affiliations

    • Department of Nuclear Medicine, Rambam Medical Center and B. Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa, Israel
    • ,
  • Rachel Bar-Shalom

      Affiliations

    • Department of Nuclear Medicine, Rambam Medical Center and B. Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa, Israel

References 

  1. Boring C, Squires T, Tong T, et al.  Cancer statistics. Ca Canc J Clin. 1994;44:7–26
  2. Smith SD, Rubin CM, Horvath A, et al.  Non-Hodgkin’s lymphoma in children. Semin Oncol. 1990;17:113–119
  3. Schoder H, Meta J, Yap C, et al.  Effect of whole-body (18)F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma. J Nucl Med. 2001;42:1139–1143
  4. Hagemeister FB. Hodgkin’s disease (the next decade). Leuk Lymph. 1996;21:53–61
  5. Canellos GP. Current strategies for early Hodgkin’s disease. Ann Oncol. 1996;7(suppl 4):S91–S93
  6. Aisenberg AC. Coherent view of Non-Hodgkin’s lymphoma. J Clin Oncol. 1995;13:2656–2675
  7. Armitage JO, Wisenburger DD, Hutchins M, et al.  Chemotherapy for diffuse large cell lymphoma—rapidly responding patients have more durable remissions. J Clin Oncol. 1986;4:160–164
  8. Coiffier B, Bryon P, Berger F, et al.  Intensive and sequential combination chemotherapy for aggressive malignant lymphomas (protocol LNH-80). J Clin Oncol. 1986;4:147–153
  9. Hoh CK, Glaspy J, Rosen P, et al.  Whole-body FDG-PET imaging for staging of Hodgkin’s disease and lymphoma. J Nucl Med. 1997;38:343–348
  10. O’Doherty MJ, Macdonald EA, Barrington SF, et al.  Positron emission tomography in the management of lymphomas. Clin Oncol. 2002;14:415–426
  11. Jerusalem G, Beguin Y, Fassotte MF, et al.  Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin’s disease. Haematologica. 2001;86:266–273
  12. Cook GJR, Fogelman I, Maisey MN. Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning (Potential for error in interpretation). Semin Nucl Med. 1996;26:308–314
  13. Barrington SF, O’Doherty MJ. Limitations of PET for imaging lymphoma. Eur J Nucl Med Mol Imaging. 2003;30(suppl 1):S117–S127
  14. Brink I, Reinhardt MJ, Hoegerle S, et al.  Increased metabolic activity in the thymus gland studied with 18F-FDG PET (Age dependency and frequency after chemotherapy). J Nucl Med. 2001;42:591–595
  15. Nakahara T, Fujii H, Ide M, et al.  FDG uptake in the morphologically normal thymus (Comparison of FDG positron emission tomography and CT). Br J Radiol. 2001;74:821–824
  16. Sugawara Y, Fisher SJ, Zasadny KR, et al.  Preclinical and clinical studies of bone marrow uptake of fluorine-1-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy. J Clin Oncol. 1998;16:173–180
  17. Sugawara Y, Zasadny KR, Kison PV, et al.  Splenic fluorodeoxyglucose uptake increased by granulocyte colony-stimulating factor therapy (PET imaging results). J Nucl Med. 1999;40:1456–1462
  18. Bar-Shalom R, Yefremov N, Guralnik L, et al.  Clinical performance of PET-CT in evaluation of cancer (Additional value for diagnostic imaging and patient management). J Nucl Med. 2003;44:1200–1209
  19. Freudenberg LS, Antoch G, Schutt P, et al.  FDG-PET-CT in re-staging of patients with lymphoma. Eur J Nucl Med Mol Imaging. 2004;31:325–329
  20. Cohade C, Mourtzikos KA, Clark DP, et al.  Utility of FDG PET-CT in patients with cutaneous T-cell lymphomas (initial evaluation). J Nucl Med. 2003;44:84P; (abstr)
  21. Bar- Shalom R, Valdivia AY, Blaufox MD. PET imaging in oncology. Semin Nucl Med. 2000;30:150–185
  22. Paul R. Comparison of Fluorine-18-2-fluorodeoxyglucose and Gallium-67 citrate imaging for detection of lymphoma. J Nucl Med. 1987;28:288–292
  23. Newman JS, Francis IR, Kaminski MS, et al.  Imaging of lymphoma with PET with 2-[F-18]fluoro-2-deoxy-D-glucose (Correlation with CT). Radiology. 1994;190:111–116
  24. Jerusalem GH, Beguin YP. Positron emission tomography in non-Hodgkin’s lymphoma (NHL) (Relationship between tracer uptake and pathological findings, including preliminary experience in the staging of low-grade NHL). Clin Lymphoma. 2002;3:56–61
  25. Friedberg JW, Chengazi V. PET scans in the staging of lymphoma (Current status). Oncologist. 2003;8:438–447
  26. Leskinen-Kallio S, Ruotsalainen U, Nagren K, et al.  Uptake of carbon-11-methionine and fluorodeoxyglucose in non-Hodgkin’s lymphoma (A PET study). J Nucl Med. 1991;32:1211–1218
  27. Hoffmann M, Kletter K, Diemling M, et al.  Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type. Ann Oncol. 1999;10:1185–1189
  28. Moog F, Bangerter M, Diederichs CG, et al.  Lymphoma (Role of whole-body 2-deoxy-2-[F-18] fluoro-D-glucose (FDG) PET in nodal staging). Radiology. 1997;203:795–800
  29. Stumpe KDM, Urbinelli M, Steinert HC, et al.  Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma (Effectiveness and comparison with computed tomography). Eur J Nucl Med. 1998;25:721–728
  30. Hoffmann M, Chott A, Puspok A, et al.  18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) does not visualize follicular lymphoma of the duodenum. Ann Hematol. 2004;83:276–281
  31. Hoffmann M, Kletter K, Becherer A, et al.  18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) for staging and follow-up of marginal zone B-cell lymphoma. Oncology. 2003;64:336–340
  32. Lapela M, Leskinen S, Minn HRI, et al.  Increased glucose metabolism in untreated Non-Hodgkin’s lymphoma (A study with positron emission tomography and Fluorine-18-Fluorodeoxyglucose). Blood. 1995;86:3522–3527
  33. Rodriguez M, Rehn S, Ahlstrom H, et al.  Predicting malignancy grade with PET in Non-Hodgkin’s lymphoma. J Nucl Med. 1995;36:1790–1796
  34. Okada J, Yoshikawa K, Itami M, et al.  Positron emission tomography using Fluorine-18-fluorodeoxyglucose in malignant lymphoma (a comparison with proliferative activity). J Nucl Med. 1992;33:325–329
  35. Okada J, Yoshikawa K, Imazeki K, et al.  The use of FDG-PET in the detection and management of malignant lymphoma (Correlation of uptake with prognosis). J Nucl Med. 1991;32:686–691
  36. Okada J, Oonish H, Yoshikawa K, et al.  FDG-PET for predicting the prognosis of malignant lymphoma. Ann Nucl Med. 1994;8:187–191
  37. Armitage JO. Drug therapy (Treatment of non Hodgkin’s lymphoma). N Engl J Med. 1993;328:1023–1030
  38. Partridge S, Timothy A, O’Doherty MJ, et al.  2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin’s disease (influence on patient management in a single institution). Ann Oncol. 2000;11:1273–1279
  39. Romer W, Schwaiger M. Positron emission tomography in diagnosis and therapy monitoring of patients with lymphoma. Clin Positron Imaging. 1998;1:101–110
  40. Sandrasegaran K, Robinson PJ, Selby P. Staging of lymphoma in adults. Clin Oncol. 1994;94:149–161
  41. Weihrauch MR, Re D, Bischoff S, et al.  Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin’s disease. Ann Hematol. 2002;81:20–25
  42. Bangerter M, Moog F, Buchmann I, et al.  Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin’s disease. Ann Oncol. 1998;9:1117–1122
  43. Sasaki M, Kuwabara Y, Koga H, et al.  Clinical impact of whole body FDG-PET on the staging and therapeutic decision-making for malignant lymphoma. Ann Nucl Med. 2002;16:337–345
  44. Jerusalem G, Warland V, Majjar F, et al.  Whole-body 18F-FDG-PET for the evaluation of patients with Hodgkin’s disease and Non-Hodgkin’s lymphoma. Nucl Med Commun. 1999;20:13–20
  45. Delbeke D, Martin WH, Morgan DS, et al.  2-deoxy-2-[F-18]fluoro-D-glucose imaging with positron emission tomography for initial staging of Hodgkin’s disease and lymphoma. Mol Imaging Biol. 2002;4:105–114
  46. Buchmann I, Reinhardt M, Elsner K, et al.  2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Cancer. 2001;91:889–899
  47. Jerusalem G, Beguin Y, Najjar F, et al.  Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin’s lymphoma (NHL). Ann Oncol. 2001;2:825–830
  48. Najjar F, Hustinx R, Jerusalem G, et al.  Positron emission tomography (PET) for staging low-grade non-Hodgkin’s lymphomas (NHL). Cancer Biother Radiopharm. 2001;16:297–304
  49. Moog F, Bangerter M, Diederichs CG, et al.  Extranodal malignant lymphoma (Detection with FDG PET versus CT). Radiology. 1998;206:475–481
  50. Moog F, Bangerter M, Kotzerke J, et al.  18-F-Fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol. 1998;16:603–609
  51. Moog F, Kotzerke J, Reske SN. FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma. J Nucl Med. 1999;40:1407–1413
  52. Rini JN, Leonidas JC, Tomas MB, et al.  18F-FDG PET versus CT for evaluating the spleen during initial staging of lymphoma. J Nucl Med. 2003;44:1072–1074
  53. Carr R, Barrington SF, Madan B, et al.  Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood. 1998;91:3340–3346
  54. Kostakoglu L, Goldsmith SJ. Positron emission tomography in lymphoma (Comparison with computed tomography and Gallium-67 single photon emission computed tomography). Clin Lymphoma. 2000;1:67–74
  55. Klose T, Leidl R, Buchmann I, et al.  Primary staging of lymphomas (cost-effectiveness of FDG-PET versus computed tomography). Eur J Nucl Med. 2000;27:1457–1464
  56. Schiepers C, Filmont JE, Czernin J. PET for staging of Hodgkin’s disease and non-Hodgkin’s lymphoma. Eur J Nucl Med Mol Imaging. 2003;30(suppl 1):S82–S88
  57. Radford JA, Cowan RA, Flanagan M, et al.  The significance of residual mediastinal abnormality on the chest radiograph following treatment for Hodgkin’s disease. J Clin Oncol. 1988;6:940–946
  58. Surbone A, Longo DL, DeVita VT, et al.  Residual abdominal masses in aggressive non-Hodgkin’s lymphoma after combination chemotherapy (significance and management). J Clin Oncol. 1988;6:1832–1837
  59. Reske SN. PET and restaging of malignant lymphoma including residual masses and relapse. Eur J Nucl Med Mol Imaging. 2003;30(suppl 1):S89–S96
  60. Iosilevsky G, Front D, Bettman L, et al.  Uptake of Gallium-67 citrate and [2–3H] deoxyglucose in the tumor model, following chemotherapy and radiotherapy. J Nucl Med. 1985;26:278–282
  61. Coiffier B. How to interpret the radiological abnormalities that persist after treatment in non-Hodgkin’s lymphoma patients?. Ann Oncol. 1999;10:1141–1143
  62. Jochelson M, Mauch P, Balikian J, et al.  The significance of the residual mediastinal mass in treated Hodgkin’s disease. J Clin Oncol. 1985;3:637–640
  63. Cremerius U, Fabry U, Neuerburg J, et al.  Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma. Nucl Med Commun. 1998;19:1055–1063
  64. Zinzani PL, Magagnoli M, Chierichetti F, et al.  The role of positron emission tomography (PET) in the management of lymphoma patients. Ann Oncol. 1999;10:1181–1184
  65. Jerusalem G, Beguin Y, Fassotte MF, et al.  Whole-body positron emission tomography using 18F-fluorodeoxyglucose for post-treatment evaluation in Hodgkin’s disease and non-Hodgkin’s lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood. 1999;94:429–433
  66. Lavely WC, Delbeke D, Greer JP, et al.  FDG PET in the follow-up management of patients with newly diagnosed Hodgkin and non-Hodgkin lymphoma after first-line chemotherapy. Int J Radiat Oncol Biol Phys. 2003;57:307–315
  67. Mikhaeel NG, Timothy AR, O’Doherty MJ, et al.  18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin’s Lymphoma-comparison with CT. Leuk Lymphoma. 2000;39:543–553
  68. Spaepen K, Stroobants S, Dupont P, et al.  Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin’s lymphoma (Is [18F]FDG-PET a valid alternative to conventional diagnostic methods?). J Clin Oncol. 2001;19:414–419
  69. Naumann R, Vaic A, Beuthien-Baumann B, et al.  Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin’s disease and non-Hodgkin’s lymphoma. Br J Haematol. 2001;115:793–800
  70. Montravers F, McNamara D, Landman-Parker J, et al.  [(18)F]FDG in childhood lymphoma (clinical utility and impact on management). Eur J Nucl Med Mol Imaging. 2002;29:1155–1165
  71. Weihrauch MR, Re D, Scheidhauer K, et al.  Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood. 2001;98:2930–2934
  72. Dittmann H, Sokler M, Kollmannsberger C, et al.  Comparison of 18FDG-PET with CT scans in the evaluation of patients with residual and recurrent Hodgkin’s lymphoma. Oncol Rep. 2001;8:1393–1399
  73. Spaepen K, Stroobants S, Dupont P, et al.  Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin’s disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?. Br J Haematol. 2001;115:272–278
  74. de Wit M, Bohuslavizki KH, Buchert R, et al.  18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin’s lymphoma. Ann Oncol. 2001;12:29–37
  75. Hueltenschmidt B, Sautter-Bihl ML, Lang O, et al.  Whole body positron emission tomography in the treatment of Hodgkin disease. Cancer. 2001;91:302–310
  76. Mikhaeel NG, Timothy AR, Hain SF, et al.  18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas. Ann Oncol. 2000;11(suppl 1):147–150
  77. de Wit M, Bumann D, Beyer W, et al.  Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. Ann Oncol. 1997;8(suppl 1):57–60
  78. Cremerius U, Fabry U, Kroll U, et al.  Clinical value of FDG PET for therapy monitoring of malignant lymphoma-results of a retrospective study in 72 patients. Nuklearmedizin. 1999;38:24–30
  79. Bar Shalom R, Mor M, Yefremov N, et al.  The value of Ga-67 scintigraphy and F-18 fluorodeoxyglucose positron emission tomography in staging and monitoring the response of lymphoma to treatment. Sem Nucl Med. 2001;31:177–190
  80. Bangerter M, Kotzerke J, Griesshammer M, et al.  Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest. Acta Oncol. 1999;38:799–804
  81. Jerusalem G, Beguin Y, Fassotte MF, et al.  Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin’s disease. Ann Oncol. 2003;14:123–130
  82. Front D, Bar-Shalom R, Mor M, et al.  Aggressive non-Hodgkin lymphoma (Early prediction of outcome with Ga67 scintigraphy). Radiology. 2000;214:253–257
  83. Hoekstra OS, Ossenkoppele GJ, Golding R, et al.  Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy. J Nucl Med. 1993;34:1706–1710
  84. Dimitrakopoulou-Strauss A, Strauss LG, Goldschmidt H, et al.  Evaluation of tumor metabolism and multi-drug resistance in patients with treated malignant lymphomas. Eur J Nucl Med. 1995;22:434–442
  85. Wiedmann E, Baican B, Hertel A, et al.  Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin’s disease. Leuk Lymphoma. 1999;34:545–551
  86. Jerusalem G, Beguin Y, Fassotte MF, et al.  Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin’s lymphoma. Haematologica. 2000;85:613–618
  87. Kostakoglu L, Coleman M, Leonard JP, et al.  PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin’s disease. J Nucl Med. 2002;43:1018–1027
  88. Spaepen K, Stroobants S, Dupont P, et al.  Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma. Ann Oncol. 2003;13:1356–1363
  89. Torizuka T, Nakamura F, Kanno T, et al.  Early therapy monitoring with FDG-PET in aggressive non-Hodgkin’s lymphoma and Hodgkin’s lymphoma. Eur J Nucl Med Mol Imaging. 2004;31:22–28
  90. Becherer A, Mitterbauer M, Jaeger U, et al.  Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation. Leukemia. 2002;16:260–267
  91. Cremerius U, Fabry U, Wildberger JE, et al.  Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin’s lymphoma. Bone Marrow Transplant. 2002;30:103–111
  92. Filmont JE, Czernin J, Yap C, et al.  Value of F-18 fluorodeoxyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem-cell transplantation. Chest. 2003;124:608–613
  93. Spaepen K, Stroobants S, Dupont P, et al.  Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood. 2003;102:53–59
  94. Torizuka T, Zasadny KR, Kison PV, et al.  Metabolic response of non-Hodgkin’s lymphoma to 131I-anti-B1 radioimmunotherapy (Evaluation with FDG PET). J Nucl Med. 2000;41:999–1005
  95. Shen YY, Kao A, Yen RF. Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma. Oncol Rep. 2002;9:321–325
  96. Van den Bossche B, Lambert B, De Winter F, et al.  18-FDG PET versus high-dose Ga-67 scintigraphy for restaging and treatment follow up of lymphoma patients. Nucl Med Commun. 2002;23:1079–1083
  97. Wirth A, Seymour JF, Hicks RJ, et al.  Fluorine-18 fluorodeoxyglucose positron emission tomography, Gallium-67 scintigraphy and conventional staging for Hodgkin’s disease and Non-Hodgkin’s lymphoma. Am J Med. 2002;112:262–268
  98. Kostakoglu L, Leonard JP, Kuji I, et al.  Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma. Cancer. 2002;94:879–888
  99. Bar-Shalom R, Yefremov N, Haim N, et al.  Camera-based FDG PET and Ga-67 SPECT in evaluation of lymphoma (comparative study). Radiology. 2003;227:353–360
  100. Rini JN, Manalili EY, Hoffman MA, et al.  F-18 FDG versus Ga-67 for detecting splenic involvement in Hodgkin’s disease. Clin Nucl Med. 2002;27: 572–527
  101. Zijlstra JM, Hoekstra O, Raijmaker PGH, et al.  18-FDG positron emission tomography versus Ga-67 scintigraphy as prognostic test during chemotherapy for non-Hodgkin’s lymphoma. Brit J Haemat. 2003;123:454–462
  102. Kostakoglu L, Goldsmith S. Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow up of lymphoma (Is it time to shift gears?). Eur J Nucl Med. 2000;27:1564–1578

PII: S0001-2998(04)00020-0

doi: 10.1053/j.semnuclmed.2004.03.002

Seminars in Nuclear Medicine
Volume 34, Issue 3 , Pages 166-179 , July 2004

Article Tools

* Image Usage & Resolution